Equipping Biopharma’s Legal Leaders to Lead with Clarity, Drive AI-Enabled Operational Efficiency & Thrive Amid Relentless Change
The In-House Impact: Biopharma Summit arrived at a time when General Counsels across biopharma are facing a uniquely demanding 2026. FDA expectations remain unsettled, pricing reform continues to evolve, geopolitical tensions are shifting global partnerships and supply chains, and AI is reshaping how legal teams operate. In this environment, GCs must deliver sharper strategic judgment, stronger operational efficiency and clearer enterprise leadership.
This was the only US forum built exclusively for senior in-house legal leaders across early, growth and commercial stage biopharma organizations. It featured speakers from companies including Olema Oncology, Caribou Biosciences, Enveda Biosciences, Takeda Oncology, Legend Biotech, Boundless Bio and Sionna Therapeutics, the summit brought together the legal decision makers shaping how scientific assets translate into enterprise value.
This was the only place where biopharma GCs and CLOs benchmark with true peers, shared candid insight and returned with practical strategies they could implement immediately.
As in-house leaders, we operate at the intersection of strategy, risk and business growth. Hearing how others are navigating similar challenges sharpens my perspective and helps me support thoughtful decision-making across the business.
Sionna Therapeutics
Learning from other in-house counsel is so valuable, as we all deal with clients and outside counsel in a specific way. Meeting new people and building my network locally and beyond is priceless”
- Takeda Pharmaceuticals
The 7th In-House Impact: Biopharma Summit looks set to occupy a truly unique and invaluable space in the industry, geared specifically towards General Counsels and their in-house teams within Life Sciences, furthering Legal’s role as a critical business growth enabler
- Roche Diagnostics Corporation
Explore the Previous Event Guide
- Completed a two-day agenda covering regulatory volatility, AI governance, compliance strategy, and deal readiness
- 18+ senior legal leaders across biopharma organizations
- 15+ strategic panel discussions and fireside chats addressing the biggest challenges facing biopharma GCs in 2026
- 8+ hours of dedicated networking, including speed networking and roundtable discussions
- 1 event that brings together senior in-house counsel from across early-stage, growth-stage, and commercial biopharma
Previous Partners
Attending Companies Included
Explore the Agenda
Discover the strategies biopharma GCs are using to navigate FDA shifts, pricing reform, AI governance and crossborder risk across two focused days of curated sessions.
Partner With Us
Showcase your expertise to the in-house community and position your brand as a trusted partner shaping biopharma legal strategy in 2026.
Join Biopharma Legal Leaders
Connect with senior in-house counsel from leading biotechs and pharmaceutical companies during highvalue networking designed for meaningful GCtoGC exchange.